## Right-of-use assets

### Cost
| | (in € millions) |
|---|---|
| At January 1, 2024 | 684 |
| Increases | 16 |
| Decreases | (117) |
| Exchange differences | 3 |
| **At September 30, 2024** | **586** |

### Accumulated depreciation and impairment loss
| | (in € millions) |
|---|---|
| At January 1, 2024 | (384) |
| Depreciation charge | (33) |
| Impairment charge | (12) |
| Decreases | 81 |
| Exchange differences | (3) |
| **At September 30, 2024** | **(351)** |

#### Cost, net accumulated depreciation and impairment loss
| | (in € millions) |
|---|---|
| At January 1, 2024 | 300 |
| **At September 30, 2024** | **235** |

During the nine months ended September 30, 2024, we recorded €12 million of impairment charges for right-of-use assets in connection with our strategic decision to reduce our real estate footprint in certain locations and initiate subleases of these leased office spaces ("Office Space Optimization Initiative").

## Lease liabilities

| | 2024 | 2023 |
|---|---|---|
| **At January 1** | 558 | 613 |
| Increases | 16 | 22 |
| Payments | (84) | (84) |
| Interest expense | 27 | 29 |
| Lease incentives received (1) | (3) | 2 |
| Exchange differences | 0 | 3 |
| **At September 30** | **514** | **585** |

(1) €27 million and €29 million of interest paid on lease liabilities are included in operating activities and €57 million and €65 million of payments of lease liabilities included in financing activities within the interim condensed consolidated statement of cash flows for the nine months ended September 30, 2024 and 2023, respectively.

(2) €2 million of lease incentives received are included in financing activities within the interim condensed statement of cash flows for the nine months ended September 30, 2023. There were no lease incentives received during the nine months ended September 30, 2024.
